Testosterone Therapy Telehealth: What Operators Must Know

At Bask Health, our virtual clinic infrastructure supports men's health operators building clinical programs across multiple conditions. The Health Resources and Services Administration (HRSA) defines telehealth as the use of electronic information and telecommunications technologies to support long-distance clinical health care, and testosterone therapy is one condition for which telehealth is delivering meaningful improvements in patient access. This guide covers what testosterone therapy telehealth is, the regulatory requirements governing it in 2026, and what a compliant TRT telehealth program requires to build and operate.

Key Takeaways

• Testosterone is a DEA Schedule III controlled substance under the Anabolic Steroid Control Act. Its prescribing via telehealth is governed by the DEA's controlled substance telemedicine rules, not the same framework that applies to non-scheduled medications like GLP-1s.
• The DEA's Fourth Temporary Extension, effective January 1, 2026, and running through December 31, 2026, allows Schedule III controlled substances, including testosterone, to be prescribed via telehealth without a prior in-person visit.
• DEA rules for Schedule III telehealth prescribing require synchronous communication, meaning a live video or phone visit. Asynchronous questionnaire-only intake is not legally sufficient for testosterone prescribing under current DEA rules.
• In June 2026, HHS announced FDA-requested label updates for testosterone therapy products, removing the limitation of use for age-related hypogonadism based on TRAVERSE trial data showing no meaningful increase in cardiovascular risk.
• Diagnosis of hypogonadism requires both clinical symptoms and confirmed low serum testosterone on at least two morning measurements, per Endocrine Society guidelines. Lab work is a required part of the clinical evaluation, not optional.
• According to Telehealth.HHS.gov, telehealth is appropriate for concerns such as symptoms of low testosterone, including virtual visits for assessment, medication follow-up, and care coordination.
• Bask Health's platform supports synchronous telehealth workflows, integrated e-prescribing, and patient management to coordinate ongoing TRT care.

The TRT Telehealth Opportunity in 2026

Low testosterone, clinically termed hypogonadism, is a condition affecting a significant and growing number of men. Symptoms including fatigue, reduced libido, decreased muscle mass, increased body fat, mood changes, and reduced cognitive clarity are common but underdiagnosed because men historically avoided seeking medical care for them. Telehealth changes that dynamic by removing the barriers that kept men from engaging with care: the inconvenience of in-person appointments, the stigma of discussing sensitive health concerns face-to-face, and the geographic distance from appropriate specialists.

According to Telehealth.HHS.gov's men's health guidance, telehealth is appropriate for concerns including symptoms of low testosterone, and virtual visits can be used for screening, assessment, medication follow-up, and care coordination. The federal government's own clinical guidance explicitly endorses telehealth as a delivery mechanism for TRT care, which confirms the legitimacy of the clinical model.

The June 2026 regulatory environment has also shifted in a direction that supports access to TRT. HHS announced that the FDA has requested updated testosterone therapy product label changes, removing the limitation of use stating that safety and effectiveness had not been established for men with age-related hypogonadism. This update is based on the TRAVERSE trial, a large clinical study involving more than 5,200 men that found no meaningful increase in the risk of major adverse cardiovascular events, including heart attack and stroke, among men receiving testosterone replacement therapy. The label update removes a significant clinical uncertainty that had historically made some providers hesitant to prescribe testosterone for age-related low T.

For healthcare operators, these developments collectively signal a market that is growing, clinically validated, and increasingly well supported by federal guidance. The compliance requirements, however, require careful attention.

The Critical Regulatory Distinction: TRT Is Not GLP-1

This is the most important point for any operator building a testosterone therapy telehealth program to understand before designing the clinical model.

GLP-1 medications, including semaglutide and tirzepatide, are not DEA-scheduled controlled substances. They can be prescribed through an asynchronous care model, in which a patient submits a questionnaire, and a provider reviews it and approves treatment without a live appointment. That model works for GLP-1 programs, hair loss programs, ED treatment with PDE5 inhibitors, and many other DTC telehealth categories.

Testosterone is different. It is classified as a DEA Schedule III controlled substance under the Anabolic Steroid Control Act. Its prescribing via telehealth is governed by the DEA's controlled-substance telemedicine rules, which, as of 2026, are subject to the Fourth Temporary Extension, effective January 1, 2026.

Under these rules, prescribing a Schedule III controlled substance via telehealth requires synchronous communication between the provider and the patient. That means a live video or phone visit. It cannot be an asynchronous questionnaire review alone. A telehealth platform that allows providers to approve testosterone prescriptions based only on a patient's intake form responses, without a live clinical encounter, is operating outside DEA telemedicine rules.

This is not a gray area. Operators building a TRT telehealth program must design the care model around synchronous visits as the prescribing encounter rather than asynchronous intake.

Direct Answer: Can Testosterone Be Prescribed via Telehealth in 2026?

What a Compliant TRT Telehealth Program Actually Requires

Synchronous Clinical Encounter as the Prescribing Visit

The first and non-negotiable requirement is that the prescribing encounter is a live synchronous visit. This can be a video (preferred for documentation purposes) or a telephone call. The provider must be able to see and communicate with the patient in real time, assess their symptoms, review their lab results, and document the clinical decision before generating the prescription.

This shapes the platform requirements significantly. A TRT telehealth program needs a reliable, HIPAA-compliant video consultation capability that works across device types and connection speeds. The visit needs to be documented correctly, with the provider recording the clinical evaluation, symptom assessment, lab review, and treatment decision in the patient's clinical record.

Bask Health's platform supports synchronous video consultations within a HIPAA-compliant infrastructure, and our EMR and e-prescribing tools connect clinical encounter documentation directly to the prescription workflow, so the provider can complete the visit, document the encounter, and generate the prescription in a single, connected workflow rather than switching between systems.

Lab Work Before Prescribing

The Endocrine Society's clinical practice guidelines on male hypogonadism require diagnosis based on both clinical symptoms and confirmed low serum testosterone on at least two morning measurements using a reliable assay, along with LH and FSH levels. Prescribing testosterone without confirming the diagnosis through lab work is not consistent with the clinical standard of care and creates medical and liability risk for the prescribing provider.

For a telehealth TRT program, this means the clinical workflow needs to include ordering labs and reviewing results before the prescribing visit. Most TRT telehealth programs handle this by directing patients to a local lab before their consultation, with results delivered to the provider for review during the synchronous visit. The intake process should collect the patient's symptom history and, if available, prior testosterone levels, but the prescribing decision must be grounded in current lab data.

DEA-Registered Providers Only

Every provider prescribing testosterone in a TRT telehealth program must hold a valid DEA registration for Schedule III controlled substances. This is separate from state medical licensure and must be verified during the provider onboarding process. A provider who holds a medical license in the patient's state but does not have a DEA registration cannot legally prescribe testosterone via telehealth.

Provider onboarding for a TRT telehealth program must include DEA registration verification alongside state licensure confirmation, and ongoing monitoring of DEA registration renewals is required as part of the operational compliance program.

State PDMP Checks

Prescription Drug Monitoring Program checks are required in most states before prescribing controlled substances. The specific requirements vary by state, but the DEA's proposed permanent rule would formalize PDMP checks as a standard requirement for telehealth controlled substance prescribing. For operators building a TRT telehealth program, PDMP compliance needs to be built into the prescribing workflow from the start, with documentation of the PDMP check maintained in the patient's clinical record.

Ongoing Monitoring and Follow-Up

TRT is not a one-time prescription. Appropriate clinical management requires follow-up lab work after the initial prescribing visit to assess treatment response, monitor hematocrit (which testosterone can elevate), check estradiol levels, and evaluate any side effects. Follow-up visits at regular intervals are part of the clinical standard of care and need to be built into the program model.

For a telehealth TRT program, this means the patient management system needs to track which patients are due for follow-up labs and visits, and the clinical workflow needs to include synchronous follow-up visits at appropriate intervals rather than simply refilling prescriptions without ongoing clinical review.

Bask Health's patient management tools give clinical teams visibility into their patient population, enabling them to track which TRT patients are due for follow-up, which have outstanding lab results requiring review, and which are approaching a refill that requires a clinical evaluation before the next prescription is issued.

What the Care Model Looks Like in Practice

A compliant TRT telehealth program has a specific patient journey that differs from asynchronous DTC programs in meaningful ways:

The patient completes an initial intake form covering their symptoms, medical history, and relevant medications. The intake form is the starting point, not the clinical decision point. The patient is then directed to complete a hormone panel at a local lab, with results delivered to the clinical team. Once results are available, a synchronous video or phone visit is scheduled with a DEA-registered provider. The provider reviews the symptoms, the lab results, and the patient's overall health picture during the live visit and makes the prescribing decision—the prescription routes to a licensed pharmacy. Follow-up visits and lab checks are scheduled at clinically appropriate intervals.

This model is more operationally complex than an asynchronous program, but it is also the legally correct model for testosterone prescribing under current DEA rules. Operators who try to simplify it by removing the requirement for a synchronous visit are creating federal regulatory exposure.

Direct Answer: What Makes a TRT Telehealth Program Legally Compliant?

A legally compliant TRT telehealth program requires DEA-registered providers to conduct live synchronous video or phone consultations before prescribing; a lab-confirmed diagnosis of hypogonadism per Endocrine Society guidelines; state PDMP checks documented in the clinical record; HIPAA-compliant data handling; and ongoing clinical follow-up, including lab monitoring at appropriate intervals. The care model must be built around the synchronous visit requirement, not an asynchronous questionnaire-only workflow.

A Note From the Field

The TRT telehealth programs that run into regulatory problems are almost always the ones that tried to apply the asynchronous GLP-1 playbook to testosterone. The clinical model looks superficially similar: the patient submits health information, the provider reviews it, and a prescription is issued. But the DEA's controlled-substance rules create a fundamental difference in how that review must be conducted. Operators who understand that distinction from the start build the synchronous visit infrastructure into their program from day one. The ones who discover it after launch face a significant workflow rebuild at exactly the wrong time.

Conclusion

Telehealth for testosterone therapy is a legitimate, growing, and federally supported clinical model in 2026. The June 2026 FDA label updates removing the limitation of use for age-related hypogonadism strengthen the clinical foundation for TRT programs. The DEA's Fourth Temporary Extension preserves telehealth prescribing of Schedule III controlled substances through the end of 2026 while a permanent framework is finalized.

The compliance requirements are specific and non-negotiable: synchronous visits, DEA-registered providers, lab-confirmed diagnosis, PDMP compliance, and ongoing clinical monitoring. Operators who build these requirements into their care model from the start are building a program that can scale compliantly. Bask Health's infrastructure supports this model by covering the synchronous visit documentation, e-prescribing, patient management, and pharmacy fulfillment components required by a TRT telehealth program.

References

1. U.S. Department of Health & Human Services, Office for the Advancement of Telehealth. (n.d.). Getting started using telehealth for men’s health. https://telehealth.hhs.gov/providers/best-practice-guides/telehealth-mens-health/getting-started-using-telehealth-mens-health
2. U.S. Department of Health & Human Services. (n.d.). FDA requests updates to testosterone therapy labeling. https://www.hhs.gov/press-room/fda-requests-updates-testosterone-therapy-labeling.html
3. Health Resources and Services Administration (HRSA). (n.d.). What is telehealth? https://www.hrsa.gov/telehealth/what-is-telehealth